Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Respir Med. 2013 Sep;1(7):564-73. doi: 10.1016/S2213-2600(13)70086-9. Epub 2013 Jun 18.

Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.

Author information

1
School of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK; Aintree Chest Centre, University Hospital Aintree, Liverpool, UK. Electronic address: pmacal@liverpool.ac.uk.
2
Aintree Chest Centre, University Hospital Aintree, Liverpool, UK.

Abstract

The change in forced expiratory volume in 1 s (FEV1) after administration of a short-acting bronchodilator has been widely used to identify patients with chronic obstructive pulmonary disease (COPD) who have a potentially different disease course and response to treatment. Despite the apparent simplicity of the test, it is difficult to interpret or rely on. Test performance is affected by the day of testing, the severity of baseline lung-function impairment, and the number of drugs given to test. Recent data suggest that the response to bronchodilators is not enhanced in patients with COPD and does not predict clinical outcomes. In this Review we will discuss the insight that studies of bronchodilator reversibility have provided into the nature of the COPD, and how the abnormal physiology seen in patients with this disorder can be interpreted.

PMID:
24461617
DOI:
10.1016/S2213-2600(13)70086-9
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center